Answers are grounded in this paper and cite their sources.
Experimental analysis identifies romidepsin as a therapeutic option for osteosarcoma, suggesting novel drug targets.
The patient-derived cells have numerous genomic amplifications and deletions, consistent with derivation of the cells from the osteosarcoma itself, rather than from bystander cells
No takes yet. Share an insight, caveat, or question.
Seiden et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: